These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 26248374

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Infectious diseases. Ebola drug trials lurch ahead.
    Kupferschmidt K, Cohen J.
    Science; 2015 Feb 13; 347(6223):701-2. PubMed ID: 25678637
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The lipid moiety of brincidofovir is required for in vitro antiviral activity against Ebola virus.
    McMullan LK, Flint M, Dyall J, Albariño C, Olinger GG, Foster S, Sethna P, Hensley LE, Nichol ST, Lanier ER, Spiropoulou CF.
    Antiviral Res; 2016 Jan 13; 125():71-8. PubMed ID: 26526586
    [Abstract] [Full Text] [Related]

  • 6. Pharmacotherapy of Ebola hemorrhagic fever: a brief review of current status and future perspectives.
    Olszanecki R, Gawlik G.
    Folia Med Cracov; 2014 Jan 13; 54(3):67-77. PubMed ID: 25694097
    [Abstract] [Full Text] [Related]

  • 7. Review: Insights on Current FDA-Approved Monoclonal Antibodies Against Ebola Virus Infection.
    Tshiani Mbaya O, Mukumbayi P, Mulangu S.
    Front Immunol; 2021 Jan 13; 12():721328. PubMed ID: 34526994
    [Abstract] [Full Text] [Related]

  • 8. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
    Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S.
    Antiviral Res; 2014 May 13; 105():17-21. PubMed ID: 24583123
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The Drug Targets and Antiviral Molecules for Treatment of Ebola Virus Infection.
    Wu W, Liu S.
    Curr Top Med Chem; 2017 May 13; 17(3):361-370. PubMed ID: 27572081
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus.
    Bixler SL, Bocan TM, Wells J, Wetzel KS, Van Tongeren SA, Garza NL, Donnelly G, Cazares LH, Soloveva V, Welch L, Epstein C, Liang LF, Giesing D, Lenk R, Bavari S, Warren TK.
    Antiviral Res; 2018 Mar 13; 151():50-54. PubMed ID: 29289664
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Contemporary Anti-Ebola Drug Discovery Approaches and Platforms.
    Schneider-Futschik EK, Hoyer D, Khromykh AA, Baell JB, Marsh GA, Baker MA, Li J, Velkov T.
    ACS Infect Dis; 2019 Jan 11; 5(1):35-48. PubMed ID: 30516045
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Experimental drugs poised for use in Ebola outbreak.
    Check Hayden E.
    Nature; 2018 May 11; 557(7706):475-476. PubMed ID: 29789732
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.